Metoprolol Alvogen (Metoprolol Tartrate)

Metoprolol Alvogen is a selective β1‑adrenergic blocker that acts on the cardiovascular system to control pressure and rhythm.

• Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Post‑myocardial infarction: improves survival by reducing heart workload and preventing arrhythmias.
• Heart failure: enhances ventricular function and decreases symptoms of fluid overload.

• Metoprolol Tartrate selectively antagonizes β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation. This reduces heart rate, myocardial contractility, and cardiac output, leading to decreased oxygen consumption and lower arterial pressure. The drug’s action is dose‑dependent and primarily affects the heart without significant β2‑receptor blockade.

Metoprolol Alvogen may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Fatigue or tiredness
• Dizziness or light‑headedness
• Cold extremities
• Gastrointestinal upset (nausea, abdominal discomfort)
• Sleep disturbances (insomnia or vivid dreams)

Serious or Rare Side Effects

• Bradycardia (excessively low heart rate)
• Hypotension (significant drop in blood pressure)
• Heart block or worsening heart failure
• Bronchospasm in patients with reactive airway disease
• Severe allergic reactions (rash, swelling, anaphylaxis)

Before initiating therapy, clinicians should evaluate patient history and monitor clinical response.

• Cardiovascular assessment: confirm stable heart rate and blood pressure before dose adjustments.
• Respiratory conditions: avoid in patients with uncontrolled asthma or severe chronic obstructive pulmonary disease.
• Diabetes monitoring: watch for masking of hypoglycaemic symptoms.
• Concomitant drugs: review for potential interactions that may enhance bradycardia or hypotension.
• Renal/hepatic function: adjust dosing in impaired clearance.
• Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Metoprolol may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective beta‑blockers or other cardio‑depressants (e.g., verapamil, diltiazem) – risk of severe bradycardia.
• Potent CYP2D6 inhibitors (e.g., quinidine, paroxetine) – may increase metoprolol plasma levels.

Moderate Interactions (Monitor Closely)

• Antihypertensives (ACE inhibitors, diuretics) – additive blood‑pressure lowering effect.
• Antidiabetic agents (insulin, sulfonylureas) – may mask hypoglycaemia signs.
• NSAIDs – can reduce antihypertensive efficacy.
• Calcium channel blockers (amlodipine) – may modestly increase metoprolol concentrations.